Multiply Labs

Multiply Labs

Creates personalized vitamins and supplements

About Multiply Labs

Simplify's Rating
Why Multiply Labs is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Rating Differentiation

Industries

Healthcare

Consumer Goods

Company Size

51-200

Company Stage

Series A

Total Funding

$22.2M

Headquarters

San Francisco, California

Founded

2016

Overview

Multiply Labs specializes in creating personalized vitamins and supplements tailored to individual health needs. Their process uses advanced technology to analyze factors like age, lifestyle, and health goals, allowing them to formulate effective supplement regimens for each customer. This company primarily targets health-conscious consumers, including fitness enthusiasts and those with specific dietary requirements. Unlike many competitors, Multiply Labs operates on a direct-to-consumer model, selling products through their website and offering subscriptions for recurring revenue. Their goal is to provide customized nutritional solutions that enhance individual health and wellness.

YC Company
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for personalized medicine boosts Multiply Labs' market potential.
  • Partnerships in cell therapy manufacturing expand Multiply Labs' technological applications.
  • Advancements in 3D printing enhance Multiply Labs' product customization capabilities.

What critics are saying

  • Increased competition in personalized supplements could threaten Multiply Labs' market share.
  • Rapid tech advancements may strain Multiply Labs' R&D financial resources.
  • Regulatory challenges could impact Multiply Labs' personalized health product offerings.

What makes Multiply Labs unique

  • Multiply Labs offers 3D printed capsules, a first in the pharmaceutical market.
  • The company combines pharmaceutical science with robotics for personalized drug manufacturing.
  • Multiply Labs' direct-to-consumer model allows for tailored customer experiences and data collection.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$22.2M

Above

Industry Average

Funded Over

3 Rounds

Notable Investors:
Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Above Average

Industry standards

$15M
$8.2M
Discord
$15M
Canva
$20M
Multiply Labs
$100M
GitHub

Benefits

Work from home option

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-5%

2 year growth

-5%
Stock Titan
Sep 24th, 2024
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).

RegMedNet
May 23rd, 2024
Cell therapy weekly: Funding supports remyelination therapy for multiple sclerosis

Progentos Therapeutics, a biotech company developing a novel regenerative medicine for multiple sclerosis (MS), has launched after securing US$65 million in Series A funding.

Business Wire
May 21st, 2024
Portal Biotechnologies And Multiply Labs Announce Partnership To Automate Cell Engineering In Cell Therapy Manufacturing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform. This collaboration is an important step forward for cell therapy development and manufacturing with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more patients. “Cell therapy manufacturing infrastructure and its associated costs have severely limited the accessibility of cell therapies. Multiply Labs’ automation strategy has the potential to modularize and simplify cell therapy production to ensure greater patient impact. We are very excited to contribute to the Multiply Labs team’s vision by integrating our next generation cell engineering approach with their robotics,” said Armon Sharei, Founder and CEO of Portal. Portal’s mechanoporation technology has demonstrated the capability to deliver many different types of cargo to a broad range of cell types while preserving normal cell function

Longevity Technology
May 15th, 2024
Multiply Labs inks $85m deal with Retro Bio to automate cell therapy manufacturing

Longevity biotech Retro Biosciences has entered into an $85 million agreement with Multiply Labs to enhance the production of its cell therapies aimed at age-related diseases.

Business Wire
May 14th, 2024
Multiply Labs And Retro Biosciences Announce An $85 Million Partnership To Advance Cell Therapy Manufacturing For Age-Related Diseases

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Retro Biosciences (Retro), a biotechnology company developing therapies that meaningfully address age-related diseases, today announced a first-of-its-kind commercial and supply agreement valued at up to $85 million to automate Retro’s groundbreaking approach. Retro, supported by a recent investment by Sam Altman (CEO of OpenAI), is driven by a mission to extend healthy human lifespan by a decade, targeting the cellular drivers of aging. With this partnership, Multiply Labs marks the first commercial sale of its robotic system, in support of Retro’s efforts. This partnership underscores the versatility of Multiply Labs’ robotic systems, showcasing their wide range of cell therapy applications, which include but are not limited to CAR-T therapy manufacturing. The robotic systems can be used broadly to reduce costs, accelerate product timelines, and improve scalability for different types of cell therapies, as well as to automate manufacturing processes for both autologous and allogeneic therapies. By enabling Retro to manufacture at a cost-efficient scale, Multiply Labs empowers them to expedite the transition from process development to clinical trials and commercialization, ultimately expediting the development and delivery of life-changing therapies to patients worldwide

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Multiply Labs right now.

Find jobs on Simplify and start your career today

💡
We update Multiply Labs's jobs every 8 hours, so check again soon! Browse all jobs →